Tarsus Pharmaceuticals, Inc. (TARS)
NASDAQ:TARS
Want to see TARS full AI Analyst Report?
TARS Stock Chart & Stats
$67.24
$0.07(0.13%)
At close: 4:00 PM EST
$67.24
$0.07(0.13%)
Day’s Range― - ―
52-Week Range$38.51 - $85.25
Previous CloseN/A
Volume127.14K
Average Volume (3M)671.20K
Market Cap
$2.68B
Enterprise Value$2.67B
Total Cash (Recent Filing)$388.73M
Total Debt (Recent Filing)$88.68M
Price to Earnings (P/E)―
Beta0.17
Next Earnings
Aug 06, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.14
Shares Outstanding43,023,960
10 Day Avg. Volume725,019
30 Day Avg. Volume671,202
Financial Highlights & Ratios
PEG Ratio1.07
Price to Book (P/B)9.96
Price to Sales (P/S)7.58
P/FCF Ratio-153.35
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue4.98
Enterprise Value/Gross Profit5.51
Enterprise Value/Ebitda-68.14
Forecast
1Y Price Target
$95.17Price Target Upside41.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.71
Revenue Forecast (FY)$694.42M
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentAdvancement of TP-05 into a randomized Phase II study demonstrates meaningful clinical progress for an oral Lyme disease preventive and could support future regulatory filings if safety and tick-killing activity are confirmed.
Commercial TractionStrong XDEMVY launch with broad payer coverage and rising prescriber adoption supports the product's potential to reach blockbuster-level sales and strengthen overall revenue growth.
Regulatory PartnershipsRegulatory approval of TP-03 in Greater China and the associated partner milestone payment validate international demand and create additional regional revenue opportunities through partner commercialization.
Bears Say
International Expansion RiskUncertain regulatory pathways and mixed prescriber receptivity outside the U.S. could slow market entry and limit the scale of international sales growth.
Revenue And Profitability PressureHigh gross-to-net discounts substantially reduce reported net revenue, creating a persistent headwind to profitability despite healthy shipment volumes.
Valuation UncertaintyAnalyst models currently exclude TP-05 and certain partner milestone payments, signaling uncertainty about near-term value contribution and leaving potential upside uncaptured in present valuations.
Tarsus Pharmaceuticals News
TARS FAQ
What was Tarsus Pharmaceuticals, Inc.’s price range in the past 12 months?
Tarsus Pharmaceuticals, Inc. lowest stock price was $38.51 and its highest was $85.25 in the past 12 months.
What is Tarsus Pharmaceuticals, Inc.’s market cap?
Tarsus Pharmaceuticals, Inc.’s market cap is $2.68B.
When is Tarsus Pharmaceuticals, Inc.’s upcoming earnings report date?
Tarsus Pharmaceuticals, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 71 days.
How were Tarsus Pharmaceuticals, Inc.’s earnings last quarter?
Tarsus Pharmaceuticals, Inc. released its earnings results on May 06, 2026. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.4 by $0.24.
Is Tarsus Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Tarsus Pharmaceuticals, Inc.’s price is currently Undervalued.
Does Tarsus Pharmaceuticals, Inc. pay dividends?
Tarsus Pharmaceuticals, Inc. does not currently pay dividends.
What is Tarsus Pharmaceuticals, Inc.’s EPS estimate?
Tarsus Pharmaceuticals, Inc.’s EPS estimate is -0.22.
How many shares outstanding does Tarsus Pharmaceuticals, Inc. have?
Tarsus Pharmaceuticals, Inc. has 43,023,960 shares outstanding.
What happened to Tarsus Pharmaceuticals, Inc.’s price movement after its last earnings report?
Tarsus Pharmaceuticals, Inc. reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.4. Following the earnings report the stock price went down -1.235%.
Which hedge fund is a major shareholder of Tarsus Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in TARS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tarsus Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$95.17 (41.53% Upside)
$95.17 (41.53% Upside)
Blogger Sentiment
Bullish
TARS Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 245.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $6.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.8%
Last 30 Days ▲ 17.5%
Last 30 Days ▲ 17.5%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
42.29%
12-Months-Change
Fundamentals
Return on Equity
-14.19%
Trailing 12-Months
Asset Growth
16.05%
Trailing 12-Months
Company Description
Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
TARS Company Deck
TARS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted robust commercial momentum for XTENVI with a strong Q1 showing (>$145M, >85% YoY growth), growing prescriber adoption, improving DTC engagement (+~40% QoQ high-value activity), pipeline progress with two Phase II programs initiated and reiterated full-year guidance. Headwinds were largely expected and manageable: seasonal/deductible effects and weather impact in Q1, retreatment rates still progressing toward steady-state (~20%), limited near-term international royalties, and the one-time nature of a China milestone. Management emphasized continued execution, targeted commercial investments (Key Account Leaders), and confidence in achieving guidance and future growth drivers.View all TARS earnings summariesTARS Stock 12 Month Forecast
Average Price Target
$95.17
▲(41.53% Upside)
Technical Analysis
Denali Therapeutics
―
Arcutis Biotherapeutics
―
Beam Therapeutics
―
Disc Medicine
―
Recursion Pharmaceuticals
―
Ownership Overview
3.25% Insiders
22.64% Mutual Funds
51.10% Other Institutional Investors
11.17% Public Companies and
Individual Investors